Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study

OBJECTIVE: To examine long-term efficacy/safety of ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, added to ongoing insulin therapy in Japanese patients with type 2 diabetes. METHODS: We conducted a 36-week, open-label extension of ipragliflozin therapy following a 16-week, randomized, pl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetol Int
Asıl Yazarlar: Ishihara, Hisamitsu, Yamaguchi, Susumu, Nakao, Ikko, Asahina, Seitaro, Sakatani, Taishi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Japan 2018
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357239/
https://ncbi.nlm.nih.gov/pubmed/30800562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13340-018-0359-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller